Prognostic factors able to predict lymphoma patient's outcome are necessary to inform the patient and to choose the appropriate treatment. Beside the essential documentation of the pathological lymphoma subtype, several factors (such as age, performance status, Ann Arbor disease stage, LDH level...) easy to assess are used and help to establish prognostic indexes for each lymphoma entity. Numerous biomarkers obtained on fresh or frozen tissue using molecular techniques are currently described and may help to optimize the clinical care of lymphoma patients tomorrow.